Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers

Journal of Clinical Psychiatry

Volumn 72, Issue 2, 2011, Pages 175-182

  Bourgeois, James A ^a,d   Seritan, Andreea L ^a   Casillas, E Melina ^b,c   Hessl, David ^a,b   Schneider, Andrea ^a,b   Yang, Ying ^a   Kaur, Inderjeet ^b   Cogswell, Jennifer B ^b,c   Nguyen, Danh V ^a   Hagerman, Randi J ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; ATAXIA; CLINICAL ARTICLE; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SYNDROME; GENE MUTATION; GENETIC ASSOCIATION; HEALTH SURVEY; HETEROZYGOTE; HUMAN; MAJOR DEPRESSION; MALE; MOOD DISORDER; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SOCIAL PHOBIA; STRUCTURED INTERVIEW; TREMOR;

AGED; ANXIETY DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA MUTATIONAL ANALYSIS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PANIC DISORDER; PHENOTYPE; PHOBIC DISORDERS; RNA, MESSENGER; STRESS DISORDERS, POST-TRAUMATIC;

EID: 79951971920     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05407blu     Document Type: Article

References (72)

1. Hagerman RJ, Rivera SM, Hagerman PJ. The fragile X family of disorders: a model for autism and targeted treatments. Cur Pediat Rev. 2008;4(1): 40-52. doi:10.2174/1573960878356570 (Pubitemid 351513480)
2. Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet. 2003;72(2):454-464. doi:10.1086/36713 PubMed (Pubitemid 36194253)
3. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008;60(2):201-214.
4. Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 2000;66(1):6-15. doi:10.1086/302720 PubMed (Pubitemid 30481464)
5. Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain. 2002;125(Pt 8):1760-1771.
6. Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain. 2006;129(Pt 1):243-255. doi:10.1093/brain/awh683 PubMed (Pubitemid 43063775)
7. Dawson AJ, Chodirker BN, Chudley AE. Frequency of FMR1 premutations in a consecutive newborn population by PCR screening of Guthrie blood spots. Biochem Mol Med. 1995;56(1):63-69.
8. Dombrowski C, Lévesque S, Morel ML, et al. Premutation and intermediate- size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet. 2002;11(4):371-378. doi:10.1093/hmg/1.4.371 PubMed (Pubitemid 34213610)
9. Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation- size alleles of the FMR1 gene - and implications for the population genetics of the fragile X syndrome. Am J Hum Genet. 1995;57(5):1006-1018.
10. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet. 2001;69(2):351-360. doi:10.1086/321974 PubMed (Pubitemid 32695207)
11. Hagerman PJ. The fragile X prevalence paradox. J Med Genet. 2008;45(8):498-499.
12. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004;291(4):460-469. doi:10.101/jama.291.4.460 PubMed (Pubitemid 38129750)
13. Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005;20(2):402-412. doi:10.1093/humrep/ deh635 PubMed (Pubitemid 40277608)
14. Hagerman RJ. Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. J Dev Behav Pediatr. 2006;27(1):63-74. doi:10.1097/04703- 206020-012 PubMed (Pubitemid 44315121)
15. Hessl D, Tassone F, Loesch DZ, et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet. 2005;139B(1):115-121. doi:10.102/ajmg.b.30241 PubMed (Pubitemid 41552309)
16. Franke P, Leboyer M, Gänsicke M, et al. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res. 1998;80(2):113-127. doi:10.1016/S0165-1781(98)05-9 PubMed (Pubitemid 28414872)
17. Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention- deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006;27(suppl):S137-S144. doi:10.1097/04703- 2060402-012 PubMed (Pubitemid 44620295)
18. Reiss AL, Freund L, Abrams MT, et al. Neurobehavioral effects of the fragile X premutation in adult women: a controlled study. Am J Hum Genet. 1993;52(5):884-894.
19. Roberts JE, Bailey DB Jr, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(1):130-139.
20. Thompson NM, Rogeness GA, McClure E, et al. Influence of depression on cognitive functioning in fragile X females. Psychiatry Res. 1996;64(2):97-104. doi:10.1016/0165-1781(96)02785-0 PubMed (Pubitemid 26344771)
21. Sobesky WE, Pennington BF, Porter D, et al. Emotional and neurocognitive deficits in fragile X. Am J Med Genet. 1994;51(4):378-385. doi:10.102/ajmg. 1320510416 PubMed (Pubitemid 24197708)
22. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev. 2002;12(3):278-283. doi:10.1016/S0959-437X(02)029-X PubMed (Pubitemid 34669834)
23. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet. 2004;74(5):805-816. doi:10.1086/386296 PubMed (Pubitemid 38568956)
24. Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet. 2004;74(5):1051-1056. doi:10.1086/42070 PubMed (Pubitemid 38568975)
25. Jacquemont S, Hagerman RJ, Hagerman PJ, et al. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol. 2007;6(1):45-55. doi:10.1016/S1474-42(06)70676-7 PubMed (Pubitemid 44880272)
26. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29(4):293-302.
27. Leehey MA, Berry-Kravis E, Min SJ, et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord. 2007;22(2):203-206. doi:10.102/mds.21252 PubMed (Pubitemid 46374762)
28. Willemsen R, Mientjes E, Oostra BA. FXTAS: a progressive neurologic syndrome associated with fragile X premutation. Curr Neurol Neurosci Rep. 2005;5(5):405-410. doi:10.107/s1910-05-065-5 PubMed (Pubitemid 41419331)
29. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome - an older face of the fragile X gene. Nat Clin Pract Neurol. 2007;3(2):107-112. doi:10.1038/ncpneuro0373 PubMed (Pubitemid 46237917)
30. Jacquemont S, Leehey MA, Hagerman RJ, et al. Size bias of fragile X premutation alleles in late-onset movement disorders. J Med Genet. 2006;43(10):804-809. doi:10.136/jmg.206.042374 PubMed (Pubitemid 44654739)
31. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003;72(4):869-878. doi:10.1086/374321 PubMed (Pubitemid 36403306)
32. Jacquemont S, Farzin F, Hall D, et al. Aging in individuals with the FMR1 mutation. Am J Ment Retard. 2004;109(2):154-164.
33. Tassone F, Adams J, Berry-Kravis EM, et al. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):566-569. doi:10.102/ajmg.b.30482 PubMed (Pubitemid 46983170)
34. Cohen S, Masyn K, Adams J, et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology. 2006;67(8):1426-1431. doi:10.1212/01.wnl.0239837.57475.3a PubMed (Pubitemid 44632067)
35. Adams JS, Adams PE, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology. 2007;69(9):851-859. doi:10.1212/01.wnl.0269781.10417.7b PubMed (Pubitemid 47329584)
36. Bourgeois JA, Farzin F, Brunberg JA, et al. Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine. J Neuropsychiatry Clin Neurosci. 2006;18(2):171-177.
37. Bacalman S, Farzin F, Bourgeois JA, et al. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry. 2006;67(1):87-94. doi:10.408/JCP.v67n012 PubMed (Pubitemid 43213287)
38. Bourgeois JA, Cogswell JB, Hessl D, et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry. 2007;29(4):349-356. doi:10.1016/j.genhospsych.207.03.03 PubMed (Pubitemid 46962689)
39. Seritan AL, Nguyen DV, Farias ST, et al. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(7):1138-1144.
40. Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624-629.
41. Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID), II: multisite test-retest reliability. Arch Gen Psychiatry. 1992;49(8):630-636.
42. National Comorbidity Survey Replication (NCS-R) http://www.hcp. med.harvard.edu/ncs/. Accessed April 17, 2009.
43. Kessler RC, Abelson J, Demler O, et al. Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res. 2004;13(2):122-139.
44. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. doi:10.101/archpsyc.62.6.593 PubMed (Pubitemid 40973434)
45. Haro JM, Arbabzadeh-Bouchez S, Brugha TS, et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. Int J Methods Psychiatr Res. 2006;15(4):167-180. (Pubitemid 47047025)
46. Kessler RC, Akiskal HS, Angst J, et al. Validity of the assessment of bipolar spectrum disorders in the WHO CIDI 3.0. J Affect Disord. 2006; 96(3):259-269. doi:10.1016/j.jad.206.08.018 PubMed (Pubitemid 44827279)
47. Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415-424.
48. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 1998;33(12):587-595. doi:10.107/s012705098 PubMed (Pubitemid 28528860)
49. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-3105.
50. Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med. 1988;18(1):141-153. doi:10.1017/ S03291701975 PubMed (Pubitemid 18071642)
51. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
52. Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med. 1997;27(5):1079-1089. doi:10.1017/S03291797053 PubMed (Pubitemid 27401831)
53. Regier DA, Rae DS, Narrow WE, et al. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry suppl. 1998;173(34):24-28. (Pubitemid 28312194)
54. Weissman MM, Myers JK. Affective disorders in a US urban community: the use of research diagnostic criteria in an epidemiological survey. Arch Gen Psychiatry. 1978;35(11):1304-1311.
55. Magee WJ, Eaton WW, Wittchen H-U, et al. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53(2):159-168.
56. Grant BF, Hasin DS, Stinson FS, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(3):363-374.
57. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, comorbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747-1759. doi:10.1017/ S0329170506069 PubMed (Pubitemid 41672353)
58. Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(11):1351-1361. doi:10.408/JCP.v6n102 PubMed (Pubitemid 41779531)
59. Hessl D, Rivera S, Koldewyn K, et al. Amygdala dysfunction in men with the fragile X premutation. Brain. 2007;130(Pt 2):404-416. doi:10.1093/brain/ awl38 PubMed (Pubitemid 46181094)
60. Koldewyn K, Hessl D, Adams J, et al. Reduced hippocampal activation during recall is associated with elevated FMR1 mRNA and psychiatric symptoms in men with the fragile X premutation. Brain Imaging Behav. 2008;2(2):105-116.
61. Cornish KM, Kogan CS, Li L, et al. Lifespan changes in working memory in fragile X premutation males. Brain Cogn. 2009;69(3):551-558.
62. Kogan CS, Turk J, Hagerman RJ, et al. Impact of the fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):859-872.
63. Voon V, Saint-Cyr J, Lozano AM, et al. Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. J Neurosurg. 2005;103(2):246-251. doi:10.3171/jns.205.103.2.0246 PubMed (Pubitemid 43193899)
64. Nuyen J, Schellevis FG, Satariano WA, et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol. 2006;59(12):1274-1284. doi:10.1016/j.jclinepi.206.01.05 PubMed (Pubitemid 44708605)
65. Lauterbach EC, Freeman A, Vogel RL. Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2004;16(1):29-36.
66. Cole SA, Woodard JL, Juncos JL, et al. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1996;8(1):20-25.
67. Leentjens AFG, Van den Akker M, Metsemakers JFM, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord. 2003;18(4):414-418. doi:10.102/mds.10387 PubMed (Pubitemid 36527282)
68. Lauterbach EC, Freeman A, Vogel RL. Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cogn Behav Neurol. 2003;16(4):225-233.
69. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
70. Grigsby J, Kaye K, Robbins LJ. Reliabilities, norms and factor structure of the Behavioral Dyscontrol Scale. Percept Mot Skills. 1992;74(3):883-892.
71. Golden CJ. Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Chicago, Illinois: Skoelting; 1978:1-32.
72. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.